よくわかる関節リウマチのすべて

出版社： 永井書店
著者：
発行日： 2009-02-15
分野： 臨床医学：内科  >  膠原病/リウマチ
ISBN： 9784815918293
電子書籍版： 2009-02-15 （第1版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

7,920 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

3,960 円(税込)

購入する

商品紹介

RAの病因、病態、診断、治療、さらには介護まで広くカバーし、診療および研究の第一線で活躍をする臨床医・研究者が執筆。専門医に十分対応しながら、コメディカル、研修医、開業医の方々にも理解しやすいように配慮した。とくにRAの治療の部分に力点を置き＜負＞から＜正＞への「パラダイムシフト」の実情を余すところなく解説している。

目次

  • よくわかる関節リウマチのすべて

    ―目次―

    １　関節リウマチとはどんな病気か?(概念・定義・病態生理)
    ２　関節の構造と機能
    ３　関節リウマチは誰に起こりやすいか?(疫学，環境因子など)
    ４　関節リウマチにはどんなタイプがあるか?
    ５　どんなときに関節リウマチを考えるか?
    　　　(早期リウマチを疑わせる症状，検査異常)
    ６　関節リウマチの経過と予後
    ７　関節リウマチの診察(問診・触診など)
    ８　関節リウマチの診断に必要な血液検査
    ９　関節リウマチの診断に必要なX線検査と評価法
    10　関節リウマチの診断に必要なMRI検査と評価法
    11　関節リウマチの診断に必要な超音波検査法と評価法
    12　関節リウマチの診断基準
    13　関節リウマチの疾患活動性の判定
    14　関節リウマチの身体機能評価
    15　関節リウマチの関節外症状(肺・腎・アミロイドーシス)
    16　若年性特発性関節炎とはどんな病気か
    17　非ステロイド抗炎症薬の適応と副作用
    18　抗リウマチ薬の適応と副作用
    19　免疫抑制薬の適応と副作用
    20　ステロイド薬の適応と副作用
    21　生物学的製剤の適応と副作用
    22　関節リウマチに対するTNF阻害療法施行ガイドライン
    23　関節リウマチの関節破壊は防ぐことが可能か
    24　滑膜切除術の適応と問題点
    25　人工関節置換術の適応と問題点
    26　関節リウマチ患者の教育入院と患者指導
    27　関節リウマチのリハビリテーション
    28　関節リウマチ患者の介護
    29　関節リウマチ患者の心理と療養支援
    30　関節リウマチ専門医教育(国内外の現状)
    31　関節リウマチの薬剤経済学

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1 関節リウマチとはどんな病気か ? ( 概念・定義・病態生理 )

P.8 掲載の参考文献
(1) Fuchs HA, Kaye JJ, Callahan LF, et al : Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 16 (5) : 585-591, 1989.
 
(2) Wolfe F, Mitchell DM, Sibley JT, et al : The mortality of rheumatoid arthritis. Arthritis Rheum 37 (4) : 481-494, 1994.
PubMed
(3) Arnett FC : Revised criteria for the classification of rheumatoid arthritis. Bull Rheum Dis 38 (5) : 1-6, 1989.
PubMed
(4) Niewold TB, Harrison MJ, Paget SA : Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. Qjm 100 (4) : 193-201, 2007.
PubMed
(5) Lundberg K, Nijenhuis S, Vossenaar ER, et al : Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther 7 (3) : R458-R467, 2005.
PubMed
(6) Matsumoto I, Lee DM, Goldbach-Mansky R, et al : Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. Arthritis Rheum 48 (4) : 944-954, 2003.
 
(7) Gregersen PK, Silver J, Winchester RJ : The shared epitope hypothesis : An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30 (11) : 1205-1213, 1987.
PubMed
(8) Begovich AB, Carlton VE, Honigberg LA, et al : A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN 22) is associated with rheumatoid arthritis. Am J Hum Genet 75〈2) : 330-337, 2004.
 
(9) Suzuki A, Yamada R, Chang X, et al : Functional haplotypes of PADI 4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 34 (4) : 395-402, 2003.
PubMed
(10) Klareskog L, Padyukov L, Lorentzen J, et al : Mechanisms of disease : Genetic susceptibility and environmental triggers in the development of rheumatoid arthritis. Nat Clin Pract Rheumatol 2 (8) : 425-433, 2006.
PubMed
(11) Edwards JC, Cambridge G, Leandro MJ : B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol 20 (5) : 915-928, 2006.
PubMed
(12) Eklund KK : Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy. Immunol Rev 217 : 38-52, 2007.
PubMed
(13) Lipsky PE : Integrating biologic therapy into the comprehensive care of patients with rheumatoid arthritis. J Rheumatol Suppl 72 : 54-57, 2005.
PubMed
(14) Mclnnes IB, Schett G : Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7 (6) : 429-442, 2007.
 
(15) Lubberts E : IL-17/Th17 targeting : on the road to prevent chronic destructive arthritis? Cytokine 41 (2) : 84-91, 2008.
PubMed
(16) Kotake S, Udagawa N, Takahashi N, et al : IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103 (9) : 1345-1352, 1999.
PubMed
(17) Yamada H, Nakashima Y, Okazaki K, et al : Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Ann Rheum Dis 67 (9) : 1299-1304, 2008.
 
(18) Nishimoto N, Hashimoto J, Miyasaka N, et al : Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI) ; evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66 (9) : 1162-1167, 2007.
 

2 関節の構造と機能

P.16 掲載の参考文献
(1) Tortora GJ, Grabowski SR : Principles of Anatomy and Physiology. 9th ed, John Wiley & Sons, New York, 2000.
 
(2) Salter RB, et al : The biological effect of continuous passive motion on the healing of full-thickness defects in articular cartilage. J Bone Joint Surg 63-A : 1232-1251, 1980.
 
(3) Bruckner P, et al : D-periodic distribution of collagen type IX along cartilage fibrils. J Cell Biol 106 : 991-997, 1988.
PubMed
(4) Clark JM : The organization of collagen in cryofractured rabbit articular cartilage : a scanning electron microscopic study. J Orthop Res 3 : 17-29, 1985.
PubMed
(5) Poole AR, et al : An immunoelectron microscope study of the organization of proteoglycan monomer, link protein, and collagen in the matrix of articular cartilage. J Cell Biol 93 : 927-937, 1982.
 
(6) Redler I, et al : The ultrastructure and biomechanical significance of the tidemark of articular cartilage. Clin Orthop 112 : 357-362, 1975.
PubMed

3 関節リウマチは誰に起こりやすいか ? ( 疫学、環境因子など )

P.25 掲載の参考文献
(1) Alexander JM, Harold S, Alan SR, et al : Characterizing the quantitative genetic contribution rheumatoid arthritis using data from twins. Arthritis Rheum 43 : 30-37, 2000.
 
(2) 古野純典 : 慢性関節リウマチの有病率と発症要因に関する疫学的研究. 平成10年度厚生科学研究費補助金 : 免疫・アレルギー等研究事業研究報告書, pp 200-201, 1998.
 
(3) Doran MF, Pond GR, Crowson CS, et al : Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 46 : 625-631, 2002.
 
(4) Kaipiainen-Seppanen O, Kautiainen H : Declining trend in the incidence of rheumatoid factor-positive rheumatoid arthritis in Finland 1980-2000. J Rheumatol 33 : 2132-2138, 2006.
PubMed
(5) Nielen MMJ, Schaardenburg D, Reesink HW, et al : Specific autoantibodies precede the symptoms of rheumatoid arthritis ; A study of serial measurements in blood donors. Arthritis Rheum 50 : 380-386, 2004.
 
(6) Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al : Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48 : 2741-2749, 2003.
PubMed
(7) Linos A, Worthington JW, OFallon WM, et al : The epidemiology of rheumatoid arthritis in Rochester, Minesota ; A study of incidence, prevalence and mortality. Am J Epidemiol 111 : 87-98, 1980.
 
(8) Doran MF, Crowson CS, OFallon WM, et al : The effect of oral contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis : a population based study. J Rheumatol 31 : 207-213, 2004.
 
(9) Karison EW, Mandl LA, Hankinson SE, et al : Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis? Results from the Nurses Health Study. Arthritis Rheum 50 : 3458-3467, 2004.
 
(10) Oliver JE, Silman AJ : Risk factor for the development of rheumatoid arthritis. Scand J Rheumatol 35 : 169-174, 2006.
PubMed
(11) Silman A, Kay A, Brennan P : Timing of pregnancy relation to the onset of rheumatoid arthritis. Arthritis Rheum 35 : 152-155, 1992.
 
(12) Brennan P, Silman A : Breast-feeding and the onset of rheumatoid arthritis. Arthritis Rheum 37 : 808-813, 1994.
PubMed
(13) Hutchinson D, Shepstone L, Moots R, et al : Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), particularly in patients without a family history of RA. Ann Rheum Dis 60 : 223-227, 2001.
PubMed
(14) Padyukov L, Silva C, Stolt P, et al : A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 50 : 3085-3092, 2004.
PubMed
(15) Klareskog L, Stolt P, Lundberg K, et al : A new model for an etiology of rheumatoid arthritis ; Smoking may trigger HLA-DR (shared epitope) -restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54 : 38-46, 2006.
 
(16) Pattison DJ, Symmons DP, Lunt M, et al : Dietary beta-cryptoxanthin and inflammatory polyarthritis ; results from a population-based prospective study. Am J Clin Nutr 82 : 451-455, 2005.
PubMed
(17) Linos A, Kaklamani VG, Kaklamani E, et al : Dietary factors in relation to rheumatoid arthritis ; a role for olive oil and cooked vegetables? Am J Clin Nutr 70 : 1077-1082, 1999.
PubMed
(18) Wakitani S, Murata N, Toda Y, et al : The relationship between HLA-DRBI alleles and disease subsets of rheumatoid arthritis in Japanese. Br J Rheumatol 36 : 630-636, 1997.
 
(19) Suzuki A, Yamada R, Chang X, et al : Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 34 : 395-402, 2003.
PubMed
(20) Shiozawa S, Hayashi S, Tsukamoto Y, et al : Identification of the gene loci that predispose to rheumatoid arthritis. Int Immunol 10 : 1891-1895, 1998.
PubMed

4 関節リウマチにはどんなタイプがあるか ?

P.33 掲載の参考文献
(1) Winchester RJ : The molecular basis of susceptibility to rheumatoid arthritis. Adv Immunol 56 : 389, 1994.
 
(2) Suzuki A, Yamada R, Chang X, et al : Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 34 : 395, 2003.
PubMed
(3) 柱本照, 塩沢俊一 : リウマチ性疾患・膠原病における疾患感受性遺伝子 ; 関節リウマチ. リウマチ科 37 : 197, 2007.
 
(4) Smyth CJ : Therapy of rheuatoid arthritis ; A pyramidal plan. Postgrad Med 51 : 31, 1972.
 
(5) Monger R, Hrywnak V : Arthritis mutilans. N Engl J Med 349 : 1935, 2003.
PubMed
(6) Felty AR : Chronic arthritis in the adult associated with splenomegaly and leukopenia. Bull Johns Hopkins Hosp 35 : 16, 1924.
 
(7) Rosenthal AK, Ryan LM, McCarty DJ : Calcium pyrophosphate crystal deposition disease, pseudogout, and articular chondrocalcinosis. Arthritis and Allied Conditions, 14th ed, Koopman WJ (ed), p2348, Lippincott Williams & Wilkins, Philadelphia, 2001.
 
(8) Cantini F, Salvarani C, Olivieri I, et al : Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome ; a prospective follow up and magnetic resonance imaging study. Ann Rheum Dis 58 : 230, 1999.
PubMed

5 どんなときに関節リウマチを考えるか ? ( 早期リウマチを疑わせる症状、検査異常 )

P.39 掲載の参考文献
(1) Combe B, Landewe R, Lukas C, et al : EULAR recommendations for the management of early arthritis : report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66 : 34, 2007.
PubMed
(2) van der Helm-van Mil AH, le Cessie S, van Dongen H, et al : A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis ; how to guide individual treatment decisions. Arthritis Rheum 56 : 433, 2007.
PubMed
(3) van Gaalen FA, van Aken J, Huizinga TW, et al : Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 50 : 2113, 2004.
PubMed
(4) McQueen FM : Magnetic resonance image in early inflammatory artiritis ; what is its role? Rheumatology 39 : 700, 2000.
 
(5) Jimenez-Boj E, Nobauer-Huhmann I, Hanslik-Schnabel B, et al : Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum 56 : 1118, 2007.
 
(6) Tamai M, Kawakami A, Uetani M, et al : The presence of anti-cyclic citrullinated peptide antibody is associated with MRI detection of bone marrow oedema in early-stage rheumatoie arthritis. Ann Rheum Dis 65 : 133, 2006.
PubMed
(7) Tamai M, Kawakami A, Uetani M, et al : Early prediction of rheumatoid arthritis by serologic variables and magneric resonance imaging of the wrists and finger joints : Results from prospective clinical examination. Ann Rheum Dis 65 : 134, 2006,
 
(8) Tamai M, Kawakami A, Uetani M, et al : Bone edema determined by magnetic resonance imaging reflects severe disease status in patients with early-stage rheumatoid arthritis. J Rheumatol 34 : 2154, 2007.
PubMed

6 関節リウマチの経過と予後

P.49 掲載の参考文献
(1) Smyth CJ : Therapy of rheumatoid arthritis ; A pyramidal plan. Postgrad Med 51 : 31-39, 1972.
PubMed
(2) 當間重人 : 関節リウマチ患者を対象とした多施設共同データベースの構築と疫学研究システムの確立に関する研究. 平成19年度厚生労働科学研究費補助金 (免疫アレルギー疾患予防・治療研究事業) 研究報告書, 第1分冊, pp 30-32, 2008.
 
(3) Baecklund E, Ekbom A, Sparen P, et al : Disease activity and risk of lymphoma in patients with rheumatoid arthritis : nested case-control study. BMJ 317 (7152) : 180-181, 1998.
PubMed
(4) Baecklund E, Iliadou A, Askling J, et al : Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54 (3) : 692-701, 2006.
 
(5) Kamel OW, van de Rijn M, Weiss LM, et al : Brief report ; reversible lymphomas associated with Epstein-Barr viurs occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 328 (18) : 1317-1321, 1993.
 
(6) Shimada K, Matsui T, Kawakami M, et al : Methotrexate-related lymphomatoid granulomatosis ; A case report of spontaneous regression of large tumors in multiple organs after cessation of methotrexate therapy in rheumatoid arthritis. Scand J Med 36 (1) : 64-67, 2007.
 
(7) Cibere J, Sibley J, Haga M : Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 40 (9) : 1580-1586, 1997.
PubMed
(8) Thomas E, Brewster DH, Black RJ, et al : Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88 (3) : 497-502, 2000.
PubMed
(9) Ekstrom K, Hjalgrim H, Brandt L, et al : Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rhum 48 (4) : 963-970, 2003.
 
(10) 當間重人 : 関節リウマチ患者を対象とした多施設共同データベースの構築と疫学研究システムの確立に関する研究. 平成19年度厚生労働科学研究費補助金 (免疫アレルギー疾患予防・治療研究事業) 研究報告書, 第1分冊, pp 37-39, 2008.
 

7 関節リウマチの診察 ( 問診・触診など )

P.57 掲載の参考文献
(1) Ritchie DM, Boyle LA, Mclnnes JM, et al : Clinical studies with an articular index for the assessment of tenderness in patients with rheumatoid arthritis. QJ Med 37 : 393-406, 1968.
 
(2) 高杉潔 : 関節のみかた. リウマチ基本テキスト, 第2版, 日本リウマチ財団教育研修委員会 (編), pp160-180, 日本リウマチ財団, 東京, 2005.
 

8 関節リウマチの診断に必要な血液検査

P.65 掲載の参考文献
(1) Arnett FC, Edworthy SM, Bloch DA, et al : The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 : 315-324, 1988.
PubMed
(2) 林伸英, 西村邦宏, 森信暁雄, ほか : 関節リウマチの新しいdiagnostic testsとevaluative tests. 臨床病理 55 : 388-396, 2007.
Medical*Online
(3) Nielsen MMJ, van Schaardenburg D, Reesink HW, et al : Specific autoantibodies precede the symptoms of rheumatoid arthritis : a study of serial measurements in blood donors. Arthritis Rheum 50 : 380-386, 2004.
 
(4) Waaler E : On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathol Microbiol Immunol Scand 17 : 172-182, 1939.
 
(5) Rose HM, Ragan C, Pearce E, et al : Differentiai agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. Proc Soc Exp Biol Med 68 : 1-11, 1949.
 
(6) Parekh RB, Dwek RA, Sutton BJ, et al : Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316 : 452-457, 1985.
PubMed
(7) Wener MH : Autoantibodies and other laboratory tests. Rheumatoid Arthritis, St. Clair EW, Pisetsky DS, Haynes BF (eds), pp 64-79, Lippincott Williams & Wilkins, Philadelphia, 2004.
 
(8) 中敬彦 : 慢性関節リウマチ患者におけるIgGリウマトイド因子の臨床的意義. リウマチ 35 : 530-537, 1995.
 
(9) 熊谷俊一, 林伸英 : RAの早期診断RAの免疫学的検査. 診断と治療 91 : 783-790, 2003.
 
(10) Nienhuis RLF, Mandema EA : A new serum factor in patients with rheumatoid arthritis ; The antiperinuclear factor. Ann Rheum Dis 23 : 302-305, 1964.
 
(11) Young BJJ, Mallya RK, Leslie RDJ, et al : Anti-keratin antibodies in rheumatoid arthritis. BMJ 2 : 97-99, 1979.
 
(12) Simon M, Girbal E, Sebbag M, et al : The cytokeratin filament-aggregating protein filaggrin is the target of the socalled "antikeratin antibodies", autoantibodies specific for rheumatoid arthritis. J Clin Invest 92 : 1387-1393, 1993.
 
(13) Sebbag M, Simon M, Vincent C, et al : The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 95 : 2672-2679, 1995.
PubMed
(14) Schellekens GA, de Jong BA, vanden Hoogen FH, et al : Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101 : 273-281, 1995.
 
(15) Cantaert T, De Rycke L, Bongartz T, et al : Citrullinated proteins in rheumatoid arthritis ; crucial...but not sufficient! Arthritis Rheum 54 : 3381-3389, 2006.
 
(16) Schellekens GA, Visser H, de Jong BA, et al : The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43 : 155-163, 2000.
PubMed
(17) van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al : Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis : a prospective cohort study. Arthritis Rheum 50 : 709-715, 2004.
PubMed
(18) Gottenberg JE, Mignot S, Nicaise-Rolland P, et al : Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjogren's syndrome. Ann Rheum Dis 64 : 114-117, 2005.
 
(19) Wener MH, Hutchinson K, Morishima C, et al : Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. Arthritis Rheum 50 : 2305-2308, 2004.
PubMed
(20) Vander Cruyssen B, Hoffman IE, Zmierczak H, et al : Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 64 : 1145-1149, 2005.
PubMed
(21) Elkayam O, Segal R, Lidgi M, et al : Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis. Ann Rheum Dis 65 : 1110-1112, 2006.
PubMed
(22) Yamanaka H, Matsuda Y, Tanaka M, et al : Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 43 : 852-858, 2000.
PubMed
(23) Ribbens C, Andre B, Jaspar JM, et al : Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol 27 : 888-893, 2000.
PubMed
(24) Ribbens C, Martiny Porras M, Franchimont N, et al : Increased matrix metalloproteinase-3 serum levels in rheumatic diseases ; relationship with synovitis and steroid treatment. Ann Rheum Dis 61 : 161-166, 2002.
 
(25) Steiner G, Smolen JS : Autoantibodies in rheumatoid arthritis : prevalence and clinical significance. Rheumatoid Arthritis, 2nd ed, Firestein GS, Panayi GS, Wollheim FA (eds), pp 193-198, Oxford University Press, Oxford, 2006.
 
(26) Nishimura K, Sugiyama D, Kogata Y, et al : Meta-analysis ; diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146 : 797-808, 2007.
PubMed

9 関節リウマチの診断に必要なX線検査と評価法

P.78 掲載の参考文献
(1) 日本リウマチ学会 (訳) : リウマチ入門. 第9版, p 553, 日本リウマチ学会, 東京, 1990.
 
(2) Steinbrocker O, Traeger CH, Battermann RC : Therapeutic criteria in rheumatoid arthritis. JAMA 140 : 659-662, 1949.
 
(3) Larsen A, Dale K, Eek M : Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagnosis 18 : 481-491, 1977.
PubMed
(4) Pedowitz RA, Apple A, Speer K : Objective criteria for diagnosis of articular cartilage loss using the glenohumeral weighted abduction radiograph. The University of Pennsylvenia Orthopaedic Journal 13 : 60-64, 2000.
 
(5) Youm Y, McMurthy RY, Flatt AE, et al : Kinematics of the wrist. I. An experimental study of radio-ulnar deviation and flexion-extension. J Bone Joint Surg 60 A : 423-431, 1978.
 
(6) 越智隆弘, 木村友厚, 東文造, ほか : 慢性関節リウマチの予後診断と手術適応. 整形外科 46 : 880-888, 1995.
 
(7) Shapiro JS : A new factor in the etiology of ulnar drift. Clin Orthop 68 : 32-43, 1970.
PubMed
(8) Clayton ML, Ferlic DC : Tendon transfer for radial rotation of the wrist in rheumatoid arthritis. Clin Orthop 100 : 176-185, 1974.
PubMed
(9) Hardy RH, Clapham JCR : Observation on hallux valgus ; Based on a controlled series. J Bone Joint Surg 33 B : 376-391, 1951.
 
(10) 高倉義典, 山本晴康, 木下光雄 : 足部診療ハンドブック. p195, 医学書院, 東京, 2000.
 
(11) Bouysset M, Bonvoisin B, Lejeune E, et al : Flattering of the rheumatoid foot and tarsal arthritis on X-ray. Scand J Rheumatol 16 : 127-133, 1987.
 
(12) 三好邦達 : 先天性内反足と後部足根骨. 整形外科 21 : 427-434, 1970.
 
(13) Hinck VC, Hopkins CE : Management of the atlanto-dental interval in the adult. Am J Roentgenol 84 : 945-951, 1960.
 
(14) 藤原桂樹, 藤本真弘, 上尾光弘, ほか : 慢性関節リウマチにおける頸椎病変 : その頻度と自然経過. 整・災外 38 : 201-208, 1995.
 
(15) 武富栄二, 酒匂崇, 砂原伸彦 : 慢性関節リウマチにおける頸椎病変の画像診断. 整・災外 38 : 219-225, 1995.
 
(16) Ranawat CS, O'Leary P, Pellicci P, et al : Cervical spine fusion in rheumatoid arthritis. J Bone Joint Surg 61A : 1003-1010, 1979.
 
(17) Morizono Y, Sakou T, Kawaida H : Upper cervical involvement in rheumatoid arthritis. Spine 12 : 721-725, 1987.
PubMed
(18) Redlund-Johnel I, Petterson H : Radiographic measurements of the cranio-vertebral region. Acta Radiol Diagnosis 25 : 23-28, 1984.
 
(19) 並木脩, 西山嘉信, 山本茂樹, ほか : RA患者の脊椎病変 ; 胸腰椎病変のRheumatoid Spine LesionのX線学的診断を中心に. 日関外誌 9 : 51-60, 1990.
 

10 関節リウマチの診断に必要なMRI検査と評価法

P.87 掲載の参考文献
(1) 巨瀬勝実 : コンパクト MRI. pp 1-9, 巨瀬勝美 (編著), 共立出版, 東京, 2004.
 
(2) 住田孝之 : コンパクトMRIおよびNKT細胞を用いたRAの早期診断法の確立に関する研究. 厚生労働科学研究費補助金免疫アレルギー疾患予防・治療研究事業「RAの早期診断法の確立及び臨床経過の予測に関する研究」平成16年度総括・分担研究報告書, pp 43-48, 2005.
 
(3) 住田孝之 : コンパクトMRIによるRAの早期診断. 厚生労働科学研究費補助金免疫アレルギー疾患予防・治療研究事業「RAの早期診断法の確立及び臨床経過の予測に関する研究」平成17年度総括・分担研究報告書, pp 37-42, 2006.
 
(4) 住田孝之, 伊藤聡, 杉原誠人, ほか : コンパクトMRIによる関節破壊評価. リウマチ科 34 : 288-294, 2006.
 
(5) Yoshioka H, Ito S, Handa S, et al : Low-field compact magnetic resonance imaging system for the hand and wrist in rheumatoid arthritis. J Magn Reson Imaging 23 : 370-376, 2006.
PubMed
(6) Tamai M, Kawakami A, Uetani M, et al : Early predictin of rheumatoid arthritis by serological variables and magnetic resonance imaging of the wrists and finger joints ; results from prospective clinical examination. Ann Rheum Dis 65 : 134-135, 2006.
 
(7) Ostergaard M, Peterfy C, Conaghan P, et al : OMERACT rheumatoid arthritis magnetic resonance imaging studies ; Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 30 : 1385-1386, 2003.
PubMed

11 関節リウマチの診断に必要な超音波検査法と評価法

P.99 掲載の参考文献
(1) 佐川昭, 谷村一秀, 篠原正英, ほか : 早期リウマチはどうやって診断するか? Modern Physician 23 (9) : 1319-1323, 2003.
 
(2) van der Heijde D : Plain X-rays in rheumatoid arthritis : Overview of scoring methods, their reliability and applicability. Bailliere's Clin Rheumatol 10 : 435-455, 1996.
 
(3) Sugimoto H, et al : Early-stage rheumatoid arthritis ; Diagnostic accuracy of MR imaging. Radiology 198 : 185-192, 1996.
PubMed
(4) 佐藤靖史 : よくわかる血管のバイオロジー. pp 84-85, 羊土社, 東京, 2001.
 
(5) Rubaltelli L, Fiocco U, Cozzi L, et al : Prospective sonographic and arthroscopic evaluation of proliferative knee joint synovitis. J Ultrasound Med 13 : 855-862, 1994.
PubMed
(6) Hau M, Schultz H, Tony H-P, et al : Evaluation of pannus and vascularization of the metacarpophalangeal and proximal interphalangeal joints in rheumatoid arthritis by high resolution ultrasound. Arthritis Rheum 42 : 2303-2308, 1999.
PubMed
(7) 佐川昭, 辺見美穂子 : 関節病変をとらえる超音波画像の有用性. リウマチ科 29 : 189-194, 2003.
 
(8) 佐川昭, 辺見美穂子, 成田明宏, ほか : 画像診断. 日本臨床 63 : 400-404, 2005.
 
(9) 成田明宏, 佐川昭, 辺見美穂子 : 関節エコーでどこまでわかるか ; 有用性と限界. Medical Practice 22 : 399-401, 2005.
 
(10) 佐川昭, 成田明宏, 辺見美穂子 : 関節の画像診断. Medicina 42 : 762-765, 2005.
 
(11) 佐川昭, 成田明宏, 辺見美穂子, ほか : 超音波ドプラ法による関節炎の評価. 分子リウマチ 3 (1) : 69-76, 2006.
Medical*Online
(12) 佐川昭, 小川純子, 大裏瑞穂 : 新しい画像診断 ; MRIと超音波検査. 治療 89 (2) : 360-366, 2007.
Medical*Online
(13) 粕川禮司, 武田功, 菅野孝 : リウマチ科超音波検査アトラス. 医薬ジャーナル社, 大阪, 2002.
 
(14) 粕川禮司 (編著), 山寺幸雄 (著) : 関節血流の超音波ドプラ検査. 医歯薬出版, 東京 2007.
 
(15) 熊谷俊一, 山本一彦, 佐川昭, ほか : 関節リウマチ診療の新しい考え方. 日本内科学会雑誌 96 (10) : 121-141, 2007.
 
(16) Garlaschi G, Silvestri E, Satragno L, et al : 手のリウマチの画像診断. 佐川昭, 神島保 (訳), シュプリンガー・フェアラーク東京, 東京, 2005.
 
(17) Martino F, Silvestri E, Grassi W, et al : 骨軟部の超音波診断. 神島保, 佐川昭 (訳), シュプリンガー・ジャパン, 東京, 2008.
 

12 関節リウマチの診断基準

P.111 掲載の参考文献
(1) Arnett FC, Edworthy SM, Bloch DA, et al : The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 : 315-324, 1988.
PubMed
(2) Tamai M, Kawakami A, Uetani M, et al : Bone edema determined by magnetic resonance imaging reflects severe disease status in patients with early-stage rheumatoid arthritis. J Rheumatol 34 : 2154-2157, 2007.
PubMed
(3) Quinn MA, Emery P : Window of opportunity in early rheumatoid arthritis : possibility of altering the disease process with early intervention. Clin Exp Rheumatol 21 : S154-S157, 2003.
PubMed
(4) American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines : Guidelines for the management of rheumatoid arthritis ; 2002 Update. Arthritis Rheum 46 : 328-346, 2002.
PubMed
(5) Saraux A, Berthelot JM, Chales G, et al : Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. Arthritis Rheum 44 : 2485-2491, 2001.
PubMed
(6) Visser H, le Cessie S, Vos K, et al : How to diagnose rheumatoid arthritis early ; a prediction model for persistent (erosive) arthritis. Arthritis Rheum 46 : 357-365, 2002.
 
(7) Kondo H, Kobayashi S, Tanaka S, et al : Study on Japan Rheumatism Association diagnostic criteria for early rheumatoid arthritis : Prospective evaluation of diagnostic criteria for early rheumatoid arthritis. Ryumachi 40 : 54-59, 2000.
 
(8) 松原司, 山前邦臣, 姫野信吉, ほか : 早期リウマチ診断基準の感度と特異性. 厚生省リウマチ調査研究事業, 研究報告書, p12, 国立相模原病院, 神奈川, 1992.
 
(9) Nielen MM, van Schaardenburg D, Reesink HW, et al : Specific autoantibodies precede the symptoms of rheumatoid arthritis ; a study of serial measurements in blood donors. Arthritis Rheum 50 : 380-386, 2004.
PubMed
(10) Vencovsky J, Machacek S, Sedova L, et al : Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 62 : 427-430, 2003.
PubMed
(11) Elkayam O, Segal R, Lidgi M, et al : Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis. Ann Rheum Dis 65 : 1110-1112, 2006.
PubMed
(12) Vannini A, Cheung K, Fusconi M, et al : Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples ; citrulline-dependent or not? Ann Rheum Dis 66 : 511-516, 2007.
PubMed
(13) vander Helm-Vanmii AH, le Cessie S, van Dongen H, et al : A prediction rule for disease outcome in patients with Recent-onset undifferentiated arthritis ; How to guide individual treatment decisions. Arthritis Rheum 56 : 433-440, 2007.
 
(14) Kudo-Tanaka E, Ohshima S, Ishii M, et al : Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis. Clin Rheumatol 26 : 1627-1633, 2007.
PubMed
(15) van Gaalen FA, van Aken J, Huizinga TW, et al : Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 50 : 2113-2121, 2004.
PubMed
(16) van der Helm-van Mil AH, Verpoort KN, le Cessie S, et al : The HLA-DRB I shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum 56 : 425-432, 2007.
 
(17) Yoshioka H, Ito S, Handa S, et al : Low-field compact magnetic resonance imaging system for the hand and wrist in rheumatoid arthritis. J Magn Reson Imaging 23 : 370-376, 2006.
PubMed
(18) Taylor PC, Steuer A, Gruber J, et al : Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum 54 : 47-53, 2006.
PubMed

13 関節リウマチの疾患活動性の判定

P.118 掲載の参考文献
(1) Felson DT, et al : American College of Rheumatology : Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38 : 727-735, 1995.
PubMed
(2) Puolakka K, et al : Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis : five-year experience from the FIN-RACo trial. Arthritis Rheum 52 : 36-41, 2005.
PubMed
(3) Prevoo ML, et al : Modified disease activity scores that include twenty-eight-joint counts ; Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 : 44-48, 1995.
 
(4) Aletaha D, et al : Remission and active disease in rheumatoid arthritis ; defining criteria for disease activity states. Arthritis Rheum 52 : 2625-2636, 2005.
PubMed
(5) DASホームページ (http://www.das-score.nl/www.das-score.nl/index.html)
 
(6) Pinals RS, et al : Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 24 : 1308-1315, 1981.
PubMed
(7) Goekoop-Ruiterman YP, et al : Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study) ; a randomized, controlled trial. Arthritis Rheum 52 : 3381-3390, 2005.
PubMed
(8) Grigor C, et al : Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study) ; a single-blind randomised controlled trial. Lancet 364 : 263-269, 2004.
PubMed
(9) Fransen J, et al : Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice : a multicentre, cluster randomised controlled trial. Ann Rheum Dis 64 : 1294-1298, 2005.
 

14 関節リウマチの身体機能評価

P.127 掲載の参考文献
(1) Escalante A, et al : How much disability in rheumatoid arthritis is explained by rheumatoid arthritis? Arthritis Rheum 42 : 1712-1721, 1999.
PubMed
(2) Leigh JP, et al : Mortality predictors among 263 patients with rheumatoid arthritis. J Rheumatol 18 : 1307-1312, 1991.
PubMed
(3) Badley EM : The economic burden of musculoskeletal disorders in Canada is similar to that for cancer, and may be higher. J Rheumatol 22 : 204-206, 1995.
PubMed
(4) Mitchell JM, et al : The importance of age, education and comorbidity in the substantial earnings losses of individual with systemic polyarthritis. Arthritis Rheum 31 : 348-357, 1988.
 
(5) Yelin E, et al : The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum 30 : 507-512, 1987.
PubMed
(6) Sokka T, et al : Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 26 : 1681-1685, 1999.
PubMed
(7) Wolf F, et al : The long term of outcomes rheumatoid arthritis ; work disability ; a prospective 18 year study of 823 patients. J Rheumatol 25 : 2108-2117, 1998.
 
(8) Doherty M, et al : The 'GALS' locomotor screen. Ann Rheum Dis 51 : 1165-1169, 1992.
PubMed
(9) Guillemin F : Functional disability and quality-of O life assessment in clinical practice. Rheumatology 39 : 17-23, 2000.
 
(10) Fries JF, et al : Measurement of patient outcome in arthritis. Arthritis Rheum 23 : 137-145, 1980.
PubMed
(11) Eberhardt K, et al : Work disability in rheumatoid arthritis, Development over 15 years and elevation of predictive factors over time. J Rheumatol 34 : 481-487, 2007.
 
(12) Wolf F, et al : Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 48 : 1530-1542, 2003.
 
(13) Matsuda Y, et al : Validation of Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum 49 : 784-788, 2003.
PubMed
(14) Meenan RF, et al : AIMS2 users guide. Boston University Arthritis Center, Boston, 1991.
 
(15) Sato H, et al : Validity and reliability of a revise Japanese version of Arthritis Impact Measurement Scales version 2 (AIMS2). Modern Rheumatology 10 : 247-255, 2000.
 
(16) 橋本明, ほか : RA患者のQOL ; AIMS2改訂日本語版調査書を用いた多施設共同調査成績. リウマチ 41 : 9-24, 2001.
 
(17) Ware JF, et al : The MOS 36-item short-form health survey (SF-36), Conceptional framework and item selection. Med Care 30 : 473-483, 1992.
 
(18) SF-36ホームページ (http://www.sf-36.jp/)
 

15 関節リウマチの関節外症状 ( 肺・腎・アミロイドーシス )

P.137 掲載の参考文献
(1) Dixon WG, Watson KD, Lunt M, et al : Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor? therapy. Arthritis Rheum 56 : 2905, 2007.
PubMed
(2) Camona L, Descalzo MA, Perez-Pampin E, et al : All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 66 : 880, 2007.
 
(3) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会 (編) : 特発性間質性肺炎 ; 診断と治療の手引き. 南江堂, 東京, 2004.
 
(4) Tanaka N, Kim JS, Newell JD, et al : Rheumatoid arthritis-related lung diseases : CT findings. Radiology 232 : 81, 2004.
PubMed
(5) 奥田恭章, 高杉潔, 今井淳子, ほか : 高分解能CTによる慢性関節リウマチにおける間質性肺炎/肺線維症の検討. リウマチ 33 : 12, 1993.
 
(6) 末松栄一, 宮村知也, 嶋田裕稔, ほか : 膠原病に合併した間質性肺炎における血清マーカーKL-6およびSP-Dの臨床的検討. リウマチ 43 : 11, 2003.
 
(7) 小川法良, 下山久美子, 川端浩, ほか : 膠原病患者の間質性肺疾患に対する血清KL-6およびSP-Dの有用性に関する検討. リウマチ 43 : 19, 2003.
 
(8) Remy-Jardin M, Remy J, Cortet B, et al : Lung changes in rheumatoid arthritis : CT findings. Radiology 193 : 375, 1994.
PubMed
(9) Alarcon GS, Kremer JM, Macaluso M, et al : Risk factors for methotrexate induced lung injury in patients with rheumatoid arthritis ; A multicenter, case-control study. Ann Intern Med 127 : 356, 1997.
 
(10) Sakai F, Noma S, Kurihara Y, et al : Leflunomide-related lung injury in patients with rheumatoid arthritis : imaging features. Mod Rheumatol 15 : 173, 2005,
PubMed
(11) Wolfe F, Caplan L, Michaud K : Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia ; Association with prednisolone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy, Arthritis Rheum 54 : 628, 2006.
 
(12) Takeuchi T, Tatsuki Y, Nogami Y, et al : Post-marketing surveillance of the safety profile of infliximab in 5,000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67 : 189, 2008.
 
(13) Harigai M, Koike R, Miyasaka N : Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 357 : 1874, 2007.
PubMed
(14) Helin HJ, Korpela MM, Mustonen JT, et al : Renal biopsy findings and clinicopathlogic correlations in rheumatoid arthritis. Arthritis Rheum 38 : 242, 1995.
 
(15) Gottenberg J-E, Merle-Vincent F, Bentaberry F, et al : Anti-tumor necrosis factor α therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides. Arthritis Rheum 48 : 2019, 2003.
 

16 若年性特発性関節炎とはどんな病気か

P.150 掲載の参考文献
(1) Petty RE, et al : International League of Associations for Rheumatology classification of juvenile idiopathic arthritis ; second revision, Edmonton, 2001. J Rheumatol 31 (2) : 390-392, 2004.
PubMed
(2) 武井修治, ほか : 小慢データを利用した若年性特発性関節炎JIAの二次調査. 小児慢性特定疾患治療研究事業の登録・管理・評価・情報提供に関する研究, 平成19年度総括・分担研究報告書, pp102-113, 2008.
 
(3) 横田俊平 : 若年性関節リウマチの実態調査とQOL向上の医療・行政的政策立案. 平成12年度研究報告書, 2001.
 
(4) 武井修治, ほか : Capture-recapture法による若年性関節リウマチJRAの疾患頻度の推定. 小児慢性特定疾患治療研究事業を利活用した小児慢性疾患に関するデータベース作成とそれ以外の登録システムの統合に関する研究, 平成19年度総括・分担研究報告書, pp129-133, 2008.
 
(5) Stephan JL, et al : Macrophage activation syndrome and rheumatic disease in childhood ; A report of your new cases. Clin Exp Rheumato; 11 : 451-456, 1993.
 
(6) Takei S, et al : Serum levels of hyaluronic acid indicate the severity of joint symptoms in patients with systemic and polyarticular juvenile rheumatoid arthritis. J Rheumatol 23 : 1956-1962, 1996.
PubMed
(7) Prieur A, et al : Systemic arthritis. Arthritis in Children and adolescents, Szer IS, Kimura Y, Malleson PN, et al (eds), pp 210-222, Oxford University Press, New York, 2006.
 
(8) McDermott MF, et al : Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFRL, define a family of dominantly inherited autoinflammatory syndromes. Cell 97 (1) : 133-144, 1999.
 
(9) Miller JJ, et al : Oligoarthritis. Arthritis in Children and adolescents, Szer IS, Kimura Y, Malleson PN, et al (eds), pp 223-232, Oxford University Press, New York, 2006.
 
(10) 横田俊平, ほか : 若年性特発性関節炎 ; 初期診療の手引き (2007年). 日本小児科学会雑誌 111 (8) : 1103-1111, 2007.
 
(12) Tsujimura S, et al : Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis Rheum 52 : 1676-1683, 2005.
PubMed
(13) Gerkibu V, et al : Efficacy and safety profile of cyclosporine A in the treatment of juvenile chronic (idiopathic) arthritis ; Results of a 10-year prospective study. Rheumatology 40 : 907-913, 2001.
 
(11 Wallace C : The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum 41 : 381-391, 1998.
PubMed

17 非ステロイド抗炎症薬の適応と副作用

P.157 掲載の参考文献
(1) 森田寛, 浦部晶夫, 島田和幸, ほか : 非ステロイド抗炎症薬, 鎮痛・解熱薬, 総合感冒薬. 今日の治療薬 (2005年版), 第27版, 水島裕 (編), pp 56-115, 南江堂, 東京, 2007.
 
(2) 高崎芳成 : 関節リウマチ : 成因研究から治療の新時代へ ; 関節リウマチの治療, 薬物療法, NSAIDs概要. 日本臨牀 63 (増刊号 1) : 473-476, 2005.
 
(3) Warner TD, Giuliano F, Vojnovic I, et al : Nonsteroid drug selectivities for cyclo-oxygenase-I rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity ; a full in vitro analysis. Proc Natl Acad Sci USA 96 : 7563-7568, 1999.
PubMed

18 抗リウマチ薬の適応と副作用

P.168 掲載の参考文献
(1) van der Heijde DM : Radiographic imaging : the "gold standard" for assessment of disease progression in rheumatoid arthritis. Rheumatology 39 (suppl 1) : 9-16, 2000.
 
(2) Quinn MA, Emery P : Window of opportunity in early rheumatoid arthritis ; possibility of altering the disease process with early intervention. Clin Exp Rheumatol 21 (5 Suppl 31) : S154-S157, 2003.
 
(3) Boers M, Verhoeven AC, Markusse H, et al : Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350 : 309-318, 1997.
PubMed
(4) Anderson JJ, Well G, Verhoevwn AC, et al : Factors influencing response to treatment in rheumatoid arthritis ; the importance of disease duration. Arthritis Rheum 43 : 22-29, 2000.
 
(5) Mottonen T, Hannonen P, Korpela M, et al : Delay to institution of therapy and induction of remission using single drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46 : 894-898, 2002.
PubMed
(6) Rich E, Moreland LW, Alarcon GS : Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug. J Rheumatol 26 : 259-261, 1999.
PubMed
(7) Emery P, Breedveld FC, Dougados M, et al : Early referral recommendation for newly diagnosed rheumatoid arthritis ; evidence based development of a clinical guide. Ann Rheum Dis 61 : 290-297, 2002.
PubMed
(8) Fleson DT, Anderson JJ, Meenan RF : Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. Arthritis Rheum 35 : 1117-1125, 1992.
PubMed
(9) van der Heijde DM, van Riel PL, van Leeuwen MA, et al : Prognostic factors for radiographic dame and physical disability in early rheumatoid arthritis : A prospective follow-up study of 147 patients. Br J Rheumatol 31 : 519-525, 1992.
 
(10) Home of the DAS : Disease Activity Score in Rheumatoid arthritis (http://www.das-score.nl/).
 
(11) 鈴木康夫, 諏訪昭, 若林孝幸 : 抗リウマチ薬の選び方と使用法のコツ. 日本医師会雑誌 135 : 1057-1062, 2006.
 
(12) van Gestel AM, Anderson JJ, van Riel PL, et al : ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials ; American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol 26 : 705-711, 1998.
 
(13) Puolakka K, Kautiainen H, Mottonen T, et al : Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis ; five-year experience from the FIN-RACo trial. Arthritis Rheum 52 : 36-41, 2005.
PubMed
(14) 社団法人日本呼吸器学会薬剤性肺障害ガイドライン作成委員会 (編) : 薬剤性肺障害の評価, 治療についてのガイドライン. p 39, メディカルレビュー社, 東京, 2006.
 
(15) 鈴木康夫 : メトトレキサートによる間質性肺炎. 分子リウマチ 4 : 3-9, 2007.
Medical*Online
(16) アラバ(R) 錠全例調査 (使用成績調査) Cohort A中間報告. アベンティスファーマ株式会社, 東京, 2006.
 
(17) Suzuki Y, Uehara R, Noguchi A, et al : Elevation of hepatic aminotransferases during low-dose methotrexate therapy in rheumatoid arthritis : Risk factors and response to folic acid. Scand J Rheumatol 28 : 273-281, 1999.
PubMed
(18) Furukawa K, Ohtani T, Furukaw F, et al : Infectious mononucleosis-like syndrome induced by salazosulfapyridine in a patient with rheumatoid arthritis. Modern Rheumatol 17 : 492-495, 2007.
 
(19) 鈴木康夫, 田中千絵, 尾崎承一, ほか : メトトレキサート (MTX) により誘発されるリンパ増殖性疾患. リウマチ科 28 : 498-506, 2002.
 

19 免疫抑制薬の適応と副作用

P.178 掲載の参考文献
(1) 三森経世 : 抗リウマチ薬. 診断のマニュアルとEBMに基づく治療ガイドライン, 越智隆弘, 山本一彦, 龍順之助 (編), pp 84-98, 財団法人日本リウマチ財団, 東京, 2004.
 
(2) 山中寿 : 免疫抑制薬・生物学的製剤. 越智隆弘, 山本一彦, 龍順之助 (編), pp 99-104, 財団法人日本リウマチ財団, 東京, 2004.
 
(3) American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines : Guidelines for the management of rheumatoid arthritis ; 2002 update. Arthritis Rheum 46 : 328-346, 2002.
PubMed
(4) Goekoop-Ruiterman, YPM, et al : Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt Study) ; A randomized, controlled trial. Arthritis & Rheum 52 : 3381-3390, 2005.
 
(5) Quinn MA, et al : Very early treatment with Infliximab in addition to Methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of syno vitis and damage, with sustained benefit after Infliximab withdrawal ; Results from a twelve month randomized, double-blind, placebo controlled trial. Arthritis & Rheum 52 : 27-35, 2005.
 
(6) van der Bijl AE, et al : Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 56 : 2129-2134, 2007.
PubMed
(7) Smolen JS, et al : A proposed treatment algorithm for rheumatoid arthritis : aggressive therapy, methotrexate, and quantitative measures. Clin Exp Rheumatol 21 (5 Suppl) : S209-S210, 2003.
 
(8) 高崎芳成 : 免疫抑制剤の適応と投与法. モダンフィジシャン 20 : 69-73, 2000.
 
(9) Tanaka E, et al : Acceptability and usefulness of mizolribine in the treatment of rheumatoid arthritis in methotrexate-refractory patients and elderly patients, based on analysis of data from a large-scale observational cohort study. Mod Rheumatol 16 : 214-219, 2006.
PubMed
(10) Konndo H, et al : Efficacy and safety of tacrolimus (FK 506) in treatment of rheumatoid arthritis ; a randomized, double blind, placebo controlled dose-finding study. J Rheumatol 31 : 243-251, 2004.
 
(11) Curran MP, et al : Tacrolimus in patients with rheumatoid arthritis. Drugs 65 : 993-1001, 2005.
PubMed
(12) Kawai S, et al : Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis. J Rheumatol 33 : 2153-2161, 2006.
 
(13) McCarty DJ, et al : Intractable rheumatoid arthritis ; Treatment with combined cyclophosphamide, azathioprine, and hydroxychloroquine. JAMA 248 : 1718-1723, 1982.
PubMed
(14) Altman RD, et al : Cyclosporin A in rheumatoid arthritis ; randomized, placebo controlled dose finding study. J Rheumatol 26 : 2102-2109, 1999.
PubMed
(15) Marchesoni A, et al : Radiographic progression in early rheumatoid arthritis ; a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatol (Oxford) 42 : 1545-1549, 2003.
 

20 ステロイド薬の適応と副作用

P.185 掲載の参考文献
(1) Buttgereit F, Straub RH, Wehling M, et al : Glucocorticoids in the treatment of rheumatic diseases ; an update on the mechanisms of action. Arthritis Rheum 50 (11) : 3408-3417, 2004.
PubMed
(2) Landewe RB, Boers M, Verhoeven AC, et al : COBRA combination therapy in patients with early rheumatoid arthritis : long-term structural benefits of a brief intervention. Arthritis Rheum 46 (2) : 347-356, 2002.
PubMed
(3) American College of Rheumatology Guidelines for the management of rheumatoid arthritis ; 2002 Update. Arthritis Rheum 46 (2) : 328-346, 2002.
PubMed
(4) Kirwan JR : The effect of glucocorticoids on joint destruction in rheumatoid arthritis ; The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 333 (3) : 142-146, 1995.
 
(5) Kubota T, Nii T, Nanki T, et al : Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod Rheumatol 17 (6) : 531-533, 2007.
 

21 生物学的製剤の適応と副作用

P.200 掲載の参考文献
(1) Guidelines for the management of rheumatoid arthritis ; 2002 Update. Arthritis Rheum 46 : 328-346, 2002.
PubMed
(2) Koike R, Takeuchi T, Eguchi K, et al : Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 17 : 451-458, 2007 (http://www.ryumachi-jp.com/info/080201.html) (2008年改訂版).
 
(3) Khanna D, McMahon M, Furst DE : Safety of tumour necrosis factor-alpha antagonists. Drug Saf 27 : 307-324, 2004.
PubMed
(4) Lipsky PE, van der Heijde DM, St Clair EW, et al : Infliximab and methotrexate in the treatment of rheumatoid arthritis ; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343 : 1594-1602, 2000.
 
(5) Klareskog L, van der Heijde D, de Jager JP, et al : Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis : double-blind randomised controlled trial. Lancet 363 : 675-681, 2004.
PubMed
(6) Keystone EC, Kavanaugh AF, Sharp JT, et al : Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy ; a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50 : 1400-1411, 2004.
PubMed
(7) St Clair EW, van der Heijde DM, Smolen JS, et al : Combination of infliximab and methotrexate therapy for early rheumatoid arthritis ; a randomized, controlled trial. Arthritis and rheumatism 50 : 3432-3443, 2004.
PubMed
(8) Bathon JM, Martin RW, Fieischmann RM, et al : A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343 : 1586-1593, 2000.
 
(9) Breedveld FC, Weisman MH, Kavanaugh AF, et al : The PREMIER study ; A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 : 26-37, 2006.
 
(10) van den Berg WB, van Riel PL : Uncoupling of inflammation and destruction in rheumatoid arthritis ; myth or reality? Arthritis and rheumatism 52 : 995-999, 2005.
PubMed
(11) Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al : Comparison of treatment strategies in early rheumatoid arthritis ; a randomized trial. Ann Intern Med 146 : 406-415, 2007.
PubMed
(12) Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al : Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study) : a randomized, controlled trial. Arthritis and rheumatism 52 : 3381-3390, 2005.
PubMed
(13) Van Der Kooij S, Goekoop-Ruiterman Y, de Vries-Bouwstra J, et al : Clinical and radiological efficacy of four different treatment strategies in patients with recent onset rheumatoid arthritis : 4-year follow-up of the BeSt Study. Arthritis and rheumatism 9 (suppl) : S299, 2007.
 
(14) Bongartz T, Sutton AJ, Sweeting MJ, et al : Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies ; systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 : 2275-2285, 2006.
PubMed
(15) Wolfe F, Caplan L, Michaud K : Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia ; associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 54 : 628-634, 2006.
PubMed
(16) Askling J, Fored CM, Brandt L, et al : TNF-antagonist treatment and risk of hospitalization for infection : Results from the National Swedish Monitoring-Program for Biologics in RA (ARTIS) (Abstract). Arthritis & Rheumatism 54 : S420, 2006.
 
(17) Dixon WG, Watson K, Lunt M, et al : Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy : Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54 : 2368-2376, 2006.
PubMed
(18) TakeuchiT, Tatsuki Y, Nogami Y, et al : Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67 : 189-194, 2008.
 
(19) Koike T, Harigai M, Inokuma S, et al : Safety outcomes from a large Japanese post-marketing surveillance for etanercept. Arthritis & Rheumatism 56 : S182, 2007.
 
(20) Harigai M, Koike R, Miyasaka N : Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 357 : 1874-1876, 2007.
PubMed
(21) Baecklund E, Iliadou A, Askling J, et al : Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54 : 692-701, 2006.
 
(22) Wolfe F, Michaud K : Biologic treatment of rheumatoid arthritis and the risk of malignancy ; Analyses from a large US observational study. Arthritis Rheum 56 : 2886-2895, 2007.
PubMed
(23) Nishimoto N, Kishimoto T : Interleukin 6 ; from bench to bedside. Nature clinical practice 2 : 619-626, 2006.
PubMed
(24) Nishimoto N, Yoshizaki K, Miyasaka N, et al : Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody : a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50 : 1761-1769, 2004.
PubMed
(25) Maini RN, Taylor PC, Szechinski J, et al : Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54 : 2817-2829, 2006.
PubMed
(26) Nishimoto N, Hashimoto J, Miyasaka N, et al : Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI) ; evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66 : 1162-1167, 2007.
 

22 関節リウマチに対するTNF阻害療法施行ガイドライン

P.207 掲載の参考文献
(1) Takeuchi T, Amano K, Kameda H : Impact of TNF inhibitors on Rheumatoid Arthritis. Inflammation & Regeneration 26 : 148-159, 2006.
 
(2) Miyasaka N, Takeuchi T, Eguchi K : Proposed Japanese guidelines for the use of infliximab for Rheumatoid Arthritis. Mod Rheum 15 : 4-8, 2005.
 
(3) Miyasaka M, Takeuchi T, Eguchi K : Guidelines for the proper use of etanercept in Japan. Mod Rheum 16 : 63-67, 2006.
 
(4) Takeuchi T, Tatsuki Y, Nogami Y, et al : Post-marketing Surveillance of the Safety Profile of Infliximab in 5,000 Japanese Patients with Rheumatoid Arthritis. Ann Rheum Dis 67 : 189-194, 2008.
 
(5) Koike T, Harigai M, Inokuma S, et al : Safety outcomes from a large Japanese post-marketing surveillance for etanercept. Arthritis Rheum 56 : S182, 2007.
 
(6) エンブレルホームページ (http://www.Enbrel.jp)
 
(7) Yamanaka H, Tanaka Y, Sekiguchi N, et al : Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheum 17 : 28-32, 2007.
 
(8) Tanaka Y, Takeuchi T, Inoue E, et al : Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan : One-year clinical and radiographic outcomes (RECONFIRM-II). Mod Rheum 18 : 146-152, 2008.
 
(9) Takeuchi T, Yamanaka H, Inoue E, et al : Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan : One-year oucome of joint destruction (RECONFIRM-2J). Mod Rheum 18 : 447-452, 2008.
 
(10) Koike R, Takeuchi T, Eguchi K, et al : Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheum 17 : 451-458, 2007.
 
(11) 日本リウマチ学会ホームページ (http://www.ryumachi-jp/info/guideline.pdf)
 
(12) Abe T, Takeuchi T, Miyasaka N, et al : A multi-center, double-blind, placebo-controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheum 33 : 37-44, 2006.
 
(13) Kameda H, Ueki Y, Saito K, et al, and J-BASIC : The comparison of efficacy and safety between etanercept plus methotrexate combination therapy and etanercept monotherapy in MTX-refrectory Japanese patients with Rheumatoid Arthritis ; 52-week results from the JESMR study. Arthritis Rheumatism 58 : S531, 2008.
 
(14) Calabrese LH, Zein N, Vassilopoulos D : Safety of anti-tumor necrosis factor (anti-TNF) therapy in patients with Chronic viral infections : hepatitis C, hepatitis B, and HIC infection. Ann Rheum Dis 63 : 18-24, 2004.
 
(15) Calbrese LH, Zein N, Vassilopoulos D : Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases : assessment and preventive strategies. Ann Ruem Dis 65 : 983-989, 2006.
 
(16) Tokuda H, et al : Clinical and radiographical features of Pneumocyctis pneumoniain patients with Rheumatoid Arthritis, in comparison with Methotrexate pneumonitis and Pneumocystis pneumonia inacquired immunodeficiency syndrome ; A multicenter study. Int Med 47 : 915-923, 2008.
 
(17) Harigai M, Koike R, Miyasaka M : Pneumocystis pneumonia associated with infliximab in Japan. N Eng J Med 357 : 1874-1876, 2007.
 

23 関節リウマチの関節破壊は防ぐことが可能か

P.215 掲載の参考文献
(1) American College of Rheumatology Subcommittee on Rheumatoid arthritis guidelines : Guidelines for the management of rheumatoid arthritis ; 2002 update. Arthritis Rheum 46 : 328-346, 2002.
PubMed
(2) Combe B, Landewe R, Lukas C, et al : EULAR recommendations for the management of early arthritis : report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66 : 34-45, 2007.
PubMed
(3) Smolen JS, Aletaha D, Koeller M, et al : New therapies for treatment of rheumatoid arthritis. Lancet 370 : 1861-1874, 2007.
PubMed
(4) Seeman E, Delmas PD : Bone quality ; the material and structural basis of bone strength and fragility. N Engl J Med 354 : 2250-2261, 2006.
PubMed
(5) Cohen G, Gossec L, Dougados M, et al : Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann Rheum Dis 66 : 358-363, 2007.
PubMed
(6) Smolen JS, van Der Heijde DM, et al, and the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group : Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab ; results from the ASPIRE trial. Arthritis Rheum 54 : 702-710, 2006.
PubMed
(7) Yocum DE, et al ; Tacrolimus RA Study Group : Safety of tacrolimus in patients with rheumatoid arthritis ; long-term experience. Rheumatology 43 : 992-999, 2004.
 
(8) Yamanaka H, Tanaka Y, Sekiguchi N, et al : Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol 17 : 28-32, 2007.
 
(9) Tanaka Y, Takeuchi T, Inoue E, et al : Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan ; One-year clinical outcomes (RECONFIRM-2). Mod Rheumatol 18 : 146-152, 2008.
 
(10) Klareskog L, van der Heijde D, de Jager JP, et al ; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators : Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis ; double-blind randomised controlled trial. Lancet 363 : 675-681, 2004.
PubMed
(11) Breedveld FC, Weisman MH, Kavanaugh AF, et al ; The PREMIER study : A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 : 26-37, 2006.
 
(12) Jarrett SJ, Conaghan PG, Sloan VS, et al : Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 54 : 1410-1414, 2006.
PubMed
(13) van der Heijde D, Cohen S, Sharp JT, et al : Denosumab inhibits RANKL, reducing progression of the total Sharp score and bone erosions in patients with rheumatoid arthritis ; 12-month X-ray results [abstract]. Arthritis Rheum 56 : S698, 2007.
 
(14) Deodhar A, Dore R, Sharp J, et al : Denosumab-mediated increase of hand bone mineral density (BMD) in patients with rheumatoid arthritis is associated with decreased progression of bone erosion [abstract]. Arthritis Rheum 56 : S944, 2007.
 
(15) Nishimoto N, Hashimoto J, Miyasaka N, et al : Study of Active Controlled Monotherapy Used for Rheumatoid Arthritis, an IL-6 inhibitor (SAMURAI) ; Evidence of clinical and radiographic benefit from an X-Ray Reader-Blinded Randomized Controlled Trial of Tocilizumab. Ann Rheum Dis 66 : 1162-1167, 2007.
 
(16) Cohen SB, Emery P, Greenwald MW, et al : Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy ; Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-fourweeks (REFLEX Randamized Evaluation of Long-term Efficacy of rituximab in RA). Arthritis Rheum 54 : 2793-2806, 2006.
 
(17) Wei S, Kitaura H, Zhou P, et al : IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 115 : 282-290, 2005.
PubMed
(18) Herrak P, Gortz B, HayerS, et al : Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum 50 : 2327-2337, 2004.
 
(19) Catrina AI, af Klint E, Ernestam S, et al : Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 54 : 76-81, 2006.
PubMed

24 滑膜切除術の適応と問題点

P.220 掲載の参考文献
(1) Kanbe K, Inoue K : Efficacy of arthroscopic synovectomy for the effect attenuation cases of infliximab in rheumatoid arthritis. Clin Rheumatol 25 : 877-881, 2006.
PubMed
(2) Arthritis Foundation Committee on evaluation of synovectomy : Multicentor evaluation of synovectomy in the treatment of rheumatoid arthritis ; Report of results at the end of three years. Arthritis Rheum 20 : 765-771, 1977.
 
(3) Roch-Bras F, et al : Arthroscopic synovectomy is useful for RA as long term results (8.9 years) of arhthroscopic synovectomy. J Rheumatol 28 : 1518-1522, 2002.
 
(4) Gibbons CE, et al : Long term results (8 years) of arhthroscopic synovectomy 25 knees. J Rheumatol 26 : 98-100, 2002.
 
(5) 井上和彦, ほか : リウマチの病態生理と診断治療. 真興交易医書出版, 東京, 2001.
 
(6) Marie P, Leri A : Une variete rare de rheumatisme chronique : La Main en Lorgnette. Bull Soc Med Hosp Paris 36 : 104-107, 1913.
 
(7) 松本淳 : Arthritis mutilansと関節リウマチ. 臨床整形外科 3 : 406-414, 1968.
 
(8) Inoue Y, Inoue K, Chiba J, et al : Histological change of synovium and clinical efficacy of arthroscopic synovectomy for effect attenuation by etanercept in rheumatoid arthritis. J Tokyo Wom Med Univ 77 : 558-566, 2007.
 

26 関節リウマチ患者の教育入院と患者指導

P.238 掲載の参考文献
(1) 横山和仁, 荒記俊一 : 日本版POMS手引. 金子書房, 東京, 1994.
 
(2) 横山和仁, ほか : 診断・指導に生かすPOMS事例集. 金子書房, 東京, 2002.
 

27 関節リウマチのリハビリテーション

P.249 掲載の参考文献
(1) 日本リウマチ友の会 : 希望と自立を求めて. 2000年リウマチ白書, リウマチ患者の実態 (総合編) 211 : 78-90, 2000.
 
(2) 山本純己 : RA治療の基本的考え方. リウマチ科 27 (Suppl 1) : 568-575, 2002.
 
(3) 世界保健機関 (WHO) : 5. 生活機能と障害のモデル. International classification of functioning, disability and health (ICF) 2001 ICF国際生活機能分類 ; 国際障害分類改訂版. pp 16-18, 中央法規出版, 東京, 2002.
 
(4) 村澤章 : 関連領域の診断・評価を理解する (7) リウマチ性疾患. 臨床リハ 11 : 934-940, 2002.
 
(5) 山内寿馬, 野上貞夫, 延永正 : 慢性関節リウマチに対する局所冷凍マッサージの効果. リハ医学 14 : 47-55, 1977.
 
(6) 橋本明 : 慢性関節リウマチのプールによるリハビリテーションの実際. リウマチ科 10 : 365-376, 1993.
 
(7) Ishikawa H, Murasawa A, et al : The Senami Wrist Supporter for patients with rheumatoid arthritis. Mod Rheumatol 10 : 155-159, 2000.
PubMed
(8) 木村信子 : リウマチの自助具. 総合リハ 8 : 445-450, 1980.
 

28 関節リウマチ患者の介護

P.258 掲載の参考文献
(1) 西林保朗 : 厚生科学研究で明らかになったわが国の関節リウマチの事態. 関節外科 22 : 130-135, 2003.
 
(2) 橋本明, 佐藤元, 西林保朗, ほか : RA患者のQOL ; AIMS2改定日本語版調査票を用いた多施設共同調査成績. リウマチ 41 : 9-24, 2001.
 
(3) 西林保朗 : リウマチのエクササイズ. RA & セラピー 6 : 4-12, 2000.
Medical*Online
(4) 西林保朗, 久保仁志, 合田洋子, ほか : 関節リウマチ患者の地域医療と在宅ケア. 臨床リウマチ 18 : 239-246, 2006.
 
(5) 佐浦隆一, 秋田穂束, 黒坂昌弘 : 病病・病診連携によるRA患者のケア支援. 臨床リウマチ 18 : 247-251, 2006.
 
(6) Crosby LJ : Stress factors, emotional stress and rheumatoid arthritis disease activity. J Adv Nurse 13 : 452-461, 1988.
 
(7) 小池智子 : 慢性関節リウマチの患者の疲労感と対処行動. 医学のあゆみ 192 (3) : 256-257, 2000.
 
(8) Koike T, Kazuma K, Kawamura S : The relationship between fatigue, coping behavior, and inflammation in patient with rheumatoid arthritis. Mod Rheumatol : 10141-10149, 2000.
 
(9) 小池智子 : 慢性関節リウマチの患者の疲労感と栄養状態との関連およびこれに影響する要因. 御茶ノ水医学雑誌 48 (3・4) : 95-107, 2002.
 
(10) 日本リウマチ友の会 (編) : 2005年リウマチ白書. リウマチ患者の実態 (啓発編), 日本リウマチ友の会, 東京, 2005.
 
(11) 金澤淳則, 米延索雄 : 頸椎の手術療法. NEW MOOK整形外科 No. 1, 関節リウマチ, 越智隆弘 (編), pp 190-202, 金原出版, 東京, 1997.
 
(12) 前田真治 : 関節リウマチ患者の在宅生活への支援. MB Med Reha 71 : 23-31, 2006.
 
(13) 日本リウマチ実地医会 : リウマチのすべて : 患者と家族への説明のポイント. pp 88-90, プリメド社, 東京, 2007.
 
(14) 兵庫県立大学大学院看護学研究科21世紀COEプログラム「ユビキタス社会における災害看護拠点の形成」慢性病看護ケア方法の開発プロジェクト (編) : 災害にまけないために ; リウマチの方へ. 第3版, 2007 (http://www.coe-cnas.jp/group_chrn/manual/manual02/index.pdf).
 
(15) (社) シルバーサービス振興会 (編) : 福祉用具専門相談員研修用テキスト. pp 368-369, 中央法規出版, 東京, 2003.
 
(16) 中西徹, 畑野英治 : 関節リウマチの在宅療法. MB Med Reha 71 : 32-37, 2006.
 
(17) 柏木聡, 村澤章, 中園清, ほか : 関節リウマチ患者における介護保険の現状と今後の課題. 臨床リウマチ 18 : 252-255, 2006.
 
(18) 西林康朗, ほか : 慢性関節リウマチ患者の在宅医療の現状と介護保険制度の問題点に関する研究. 平成11年度厚生科学研究感覚器および免疫・アレルギー等研究事業報告書, pp 377-415, 2000.
 
(19) 前田真治 : RAにおける介護保険の現状. リハビリテーション医学 41 : 381-386, 2004.
 
(20) 真田弘美 (監・著), バーバラ・ブレーデン, バーバラ・ベイツージェンセン (著) : 褥瘡ケアアップデイト, 小学館, 東京, 1999.
 

29 関節リウマチ患者の心理と療養支援

P.264 掲載の参考文献
(1) 越智隆弘 (監) : 関節リウマチの薬物療法. 患者さんのための関節リウマチ治療ガイドライン, pp16-46, 医歯薬出版, 東京, 2006.
 
(1) 阿部俊子 (監) : 関節リウマチ. エビデンスに基づく疾患別看護ケア関連図, pp142-153, 中央法規出版, 東京, 2004.
 
(2) 野川道子, 佐々木栄子 : 不確かさ自己免疫疾患患者の病気の不確かさとその関連要因. 日本難病看護学会誌 8 (3) : 293-299, 2004.
 
(2) 松浦美喜雄, 浦田幸朋 (編) : 実践リウマチ・膠原病ケア. JNNスペシャル 78, 医学書院, 東京, 2006.
 
(3) 椎野泰明, 山野克明 : リウマチ性疾患の社会心理. リウマチ科 27 (増刊) : 107-115, 2002.
 
(3) 宮坂信之 : Common Diseaseインストラクションマニュアル ; 患者に何をどう説明するか. リウマチおよび関連疾患 ; 関節リウマチ. Medicina 43 (12) : 446-448, 2006.
 
(4) 宮坂信之 : 病気を識る ; 関節リウマチ, 新薬の登場でQOLの劇的改善に期待 (解説). ナース専科 25 (5) : 66-69, 2005.
 
(4) 日野原重明, 井村裕夫 (監) : 慢性関節リウマチ. 看護のための最新医学講座, 第11巻, 免疫・アレルギー疾患, pp118-134, 中山書店, 東京, 2001.
 
(5) 江口重幸, 五木田紳, 上野豪志 (訳) : 慢性の病いをもつ患者をケアするためのひとつの方法. A. クラインマン, 病の語り ; 慢性の病をめぐる臨床人類学, pp 303-332, 誠信書房, 東京, 2005.
 
(5) 松本美富士 : ケア機能障害と社会心理 ; その問題点. 日本臨床 63 (1) : 636-640, 2005.
 
(6) 越智隆弘, 山本一彦, 龍順之助 (編) : 関節リウマチの診療マニュアル ; 改訂版 ; 診断のマニュアルとEBMに基づく治療ガイドライン. 日本リウマチ財団, 東京, 2004.
 

30 関節リウマチ専門医教育 ( 国内外の現状 )

P.272 掲載の参考文献
(1) 有限責任中間法人日本リウマチ学会専門医制度規則 : 平成19年度.
 
(2) The American Board of Internal Medicine (http://www.abim.org/).
PubMed
(3) The Accreditation Council for Graduate Medical Education (http://www.acgme.org/acWebsite/home/home.asp).
 
(4) 内田詔爾 : 専門的治療 ; リウマチ医とリウマチ医療. 日本臨牀 63 (増刊号 1 : 関節リウマチ) : 607-610, 2005.
 
(5) 酒井紀 : 最近よく聞く専門医って何? 日本の専門医制度これまでとこれから. きょうの健康 7月号 : 116-120, 2004.
 
(6) 香坂俊 : 米国にみる後期研修のあり方. 週刊医学界新聞 2607号 (2004年11月1日) (http://www.igaku-shoin.co.jp/nwsppr/n2004dir/n2607dir/n260704.htm).
 
(7) Core Curriculum Outline for Rheumatology Fellowship Programs A Competency-Based Guide to Curriculum Development (http://www.rheumatology.org/educ/training/CCO.pdf).
 

31 関節リウマチの薬剤経済学

P.278 掲載の参考文献
(1) Pugner KM, Scott DI, Holmes JW, et al : The costs of rheumatoid arthritis ; an international long term review. Semin Arthritis Rheum 29 : 305-320, 2000.
PubMed
(2) Tanno M, Nakamura I, Ito K, et al : Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan ; a preliminary analysis. Mod Rhumatol 16 (2) : 77-84, 2006.
 
(3) 五十嵐中, 成倫慶, 津谷喜一郎 : 生物学的製剤の薬剤経済学. 内科 99 (4) : 666-669, 2007.
 
(4) Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al : Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study) ; A randomized, controlled trial. Arthritis Rheum 58 (2 Suppl) : S126-S135, 2008.
PubMed

書評

最近チェックした商品履歴

Loading...